Vanda Pharmaceuticals announced that its Phase III study of HETLIOZ (tasimelteon) 20 mg met its primary endpoint by shifting sleep onset 37.1 minutes earlier in adults with Delayed Sleep-Wake Phase Disorder (DSWPD) compared to placebo. Sixty percent of treated participants advanced sleep onset by at least 30 minutes, versus 15% on placebo. Vanda plans to submit these data to the FDA seeking approval for HETLIOZ as the first treatment specifically for DSWPD, a disorder affecting millions with delayed internal body clocks. Safety results were consistent with previous uses of HETLIOZ, which is already approved for other circadian rhythm disorders.
Vanda Pharmaceuticals' positive Phase III results for HETLIOZ in Delayed Sleep-Wake Phase Disorder provide context alongside Pluang's Health-sector data. As of Sep 30, 2026 05:51 WIB, 43 of 100 Health-sector US stocks rose while 56 fell. Notably, DNA gained 15.77% with a typical hold time of 9 days, contrasting with WGS which dropped 11.82% and RXRX which rose 8.65% with a longer hold time of 23 days.
GameStop's CEO Ryan Cohen and other executives have made significant insider purchases of millions of shares, showing strong confidence in the company's future despite recent stock price volatility. These buys were active decisions, not pre-scheduled...
Grass token briefly surged above $0.80, gaining over 25% in 24 hours following Multicoin Capital's investment. The DePIN project incentivizes users to share unused internet bandwidth, which is then used to process web data for AI labs. Grass plans to...
A wallet linked to Quant's founder transferred 25,776 QNT tokens valued at about $6.97 million after seven years of inactivity. The tokens were sent to several newly created wallets, while the original wallet still holds around 600,000 QNT tokens wor...
A wallet linked to Quant Network's founder moved 25,776 QNT tokens valued at $6.97 million after seven years of inactivity. The wallet still holds 600,000 QNT tokens worth $160.39 million. This transfer is significant in dollar terms but involves onl...
Concentrix Corporation reported mixed Q3 2026 results with earnings per share of $2.92, beating analyst expectations of $2.71. However, its revenue of $2.45 billion slightly missed the forecast of $2.48 billion. The company achieved a record free cas...
